



Pixium Vision co-laureate of the 7th Universal Biotech Innovation Prize among 289 candidates from 34 countries

Paris, 06 October 2015 – Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced that it had been awarded **the 7th Universal Biotech Innovation Prize**, sharing the first position with Procyron, a US company developing an innovative circulatory assist device for heart failure.

Open to international young innovative companies, academic and private researchers, the Universal Biotech Innovation Prize aims to acknowledge on an international scale, the most innovative projects in life sciences.

Khalid Ishaque, CEO of Pixium Vision, said: *“We are very pleased to have been awarded the 7th Universal Biotech Innovation Prize with such high level international innovations competing. This is a further recognition of our team’s outstanding technology at the service of blind people suffering from retinal degeneration. Pixium Vision is the only company in the world developing two distinct retinal Vision Restoration Systems. We expect to file for CE Mark for our first system, IRIS[®], before the end of 2015 for patients suffering from Retinitis Pigmentosa and progressing solidly toward the first in human implant of PRIMA, our second generation tiny wireless subretinal implant, in 2016.”*

Members of the international jury have outlined the scientific quality, robustness of both intellectual and industrial property, strong teams’ know how as well as the overall success potential in bringing a form of sight back to blind patients.

Pixium Vision’s unique technology stems from efficient academic collaboration with the Vision Institute* in Paris or Stanford University in California.

For this 7th edition, 289 applications were submitted from 34 countries. 75 selected projects were reviewed and evaluated by an international jury panel composed of well-regarded experts from the life sciences industry and European institutions, and chaired by Jean Deregnacourt, Director of Research Applications and Industrial relations at Institut Pasteur.

The Universal Biotech Innovation Prize has continuously been growing since its creation in 2009, fostering more and more innovative projects all across the globe in all the major fields of life sciences.

Contact

Pixium Vision

Pierre Kemula, CFO

investors@pixium-vision.com

+33 1 76 21 47 30

 @PixiumVision

Media Contact

Annie-Florence Loyer

*Institut de la Vision is a mixt-collaboration between the Université Pierre et Marie Curie (UMPC), the INSERM, the CNRS and the National Center for Ophthalmology, as well as the Rothschild Ophthalmology Foundation.

About Pixium Vision (www.pixium-vision.com)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision's VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. Pixium Vision plans to file IRIS's CE mark dossier before the end of 2015 and expects to launch IRIS® during the first half of 2016.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

The company is ISO 13485 certified.



Pixium Vision is listed on Euronext (Compartiment C) in Paris.
ISIN: FR0011950641; Mnemo: PIX

EURONEXT IRIS® is a trademark of Pixium-Vision SA

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R15-069 on September 23, 2015 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).